Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Front-line ruxolitinib for pediatric hemophagocytic lymphohistiocytosis
ChiCTR2000029977Phase 2Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in haemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Children's Hospital. Primary endpoint: Overall response rate at day 28. Started Jan 2019; status: recruiting.
02
Drugs
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on ChiCTR2000029977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029977.